Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | LY2503029 |
Synonyms | |
Therapy Description |
LY2503029 is AKT inhibitor, which has potential antitumor activity (Journal of Clinical Oncology 2011 29:15_suppl, e13575). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
LY2503029 | LY-2503029|LY 2503029 | Akt Inhibitor (Pan) 21 | LY2503029 is AKT inhibitor, which has potential antitumor activity (Journal of Clinical Oncology 2011 29:15_suppl, e13575). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02632994 | Expanded access | LY3023414 LY2503029 | Master Rollover Protocol for Continued Safety Assessment of Study Drug | Available | USA | 0 |